| Literature DB >> 23846919 |
Gregory T Brennan1, Valerie Relias, Muhammad Wasif Saif.
Abstract
Germline mutations in BRCA genes have been associated with pancreatic cancer. Laboratory and clinical data suggest that patients with BRCA mutations may be more responsive to therapy consisting of conventional chemotherapy with a poly(ADP-ribose) polymerase inhibitor (PARPi). The most recent data from the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting will be reviewed (Abstracts #11024 and #TPS4144).Entities:
Mesh：
Substances：
Year: 2013 PMID： 23846919 DOI： 10.6092/1590-8577/1652
Source DB: PubMed Journal: JOP ISSN： 1590-8577